Abstract
Numerous LOH and mutation analysis studies in different tumor tissues, including prostate, indicate that there are multiple tumor suppressor genes (TSGs) present within the human chromosome 8p21–22 and 10q23–24 regions. Recently, we showed that LZTS1 (or FEZ1), a putative TSG located on 8p22, has the potential to function as a cell growth modulator. We report here the cloning, gene organization, cDNA sequence characterization and expression analysis of LAPSER1, an LZTS1-related gene. This gene maps within a subregion of human chromosome 10q24.3 that has been reported to be deleted in various cancers, including prostate tumors, as frequently as the neighboring PTEN locus. The complete LAPSER1 cDNA sequence encodes a predicted protein containing various domains resembling those typically found in transcription factors (P-Box, Q-rich and multiple leucine zippers). LAPSER1 is expressed at the highest levels in normal prostate and testis, where multiple isoforms are seen, some of which are either undetectable or differentially expressed in some prostate tumor tissues and cell lines. Over-expression of LAPSER1 cDNA strongly inhibited cell growth and colony-forming efficiencies of most cancer cells assessed. Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ . 1990 J. Mol. Biol. 215: 403–410
Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB . 1996 Genomics 35: 46–54
Cabeza-Arvelaiz Y, Shih LC, Hardman N, Asselbergs F, Bilbe G, Schmitz A, White B, Siciliano MJ, Lachman LB . 1993 DNA Cell Biol. 12: 881–892
Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC, Chinault AC . 2001 Oncogene 20: 4169–4179
Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D . 1997 Cancer Res. 57: 4997–5000
Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB . 1990 Proc. Natl. Acad. Sci. USA 87: 8751–8755
Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G . 1998 Oncogene 16: 541–545
Chou PY, Fasman GD . 1978 Annu. Rev. Biochem. 47: 251–276
Courey AJ, Tjian R . 1988 Cell 55: 887–898
Dong JT, Sipe TW, Hyytinen ER, Li CL, Heise C, McClintock DE, Grant CD, Chung LW, Frierson Jr. JF . 1998 Oncogene 17: 1979–1982
Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM . 1998 Oncogene 16: 1743–1748
Foulkes NS, Sassone-Corsi P . 1996 Biochim. Biophys. Acta. 1288: F101–F121
Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M, Makamura Y . 1995 Oncogene 10: 891–895
Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW . 1997 J. Urol. 158: 636–641
Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK . 1995 Cancer Res. 55: 4800–4803
Habener JF . 1990 Mol. Endocrinol. 4: 1087–1094
Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ . 1991 Science 253: 79–82
Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I, Isaacs JT, Shimazaki J . 1994 Cancer Res. 54: 2299–2302
Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H, Croce CM . 1999 Proc. Natl. Acad. Sci. USA 96: 3928–3933
Ittmann M . 1996 Cancer Res. 56: 2143–2147
Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P . 1995 Oncogene 11: 2121–2126
Kahn T, Turazza E, Ojeda R, Bercovich A, Stremlau A, Lichter P, Poustka A, Grinstein S, zur Hausen H . 1994 Cancer Res. 54: 1305–1312
Kim SK, Ro JY, Kemp BL, Lee JS, Kwon TJ, Hong WK, Mao L . 1998 Oncogene 17: 1749–1753
Kozak M . 1991 J. Cell Biol. 115: 887–903
Lampariello F . 1994 Cytometry 15: 294–301
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R . 1997 Science 275: 1943–1947
MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R . 1996 Genomics 35: 55–65
Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P . 1993 Cell 75: 875–886
Mount SM . 1982 Nucleic Acids Res. 10: 459–472
Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL . 1996 Cancer Res. 56: 2157–2160
Narahara K, Baker E, Ito S, Yokoyama Y, Yu S, Hewitt D, Sutherland GR, Eccles MR, Richards RI . 1997 J. Med. Genet. 34: 213–216
Orikasa K, Fukushige S, Hoshi S, Orikasa S, Kondo K, Miyoshi Y, Kubota Y, Horii A . 1998 J. Hum. Genet. 43: 228–230
Petersen S, Rudolf J, Bockmuhl U, Gellert K, Wolf G, Dietel M, Petersen I . 1998 Oncogene 17: 449–454
Pirrotta V, Manet E, Hardon E, Bickel SE, Benson M . 1987 EMBO J. 6: 791–799
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV . 1997 Nat. Genet. 15: 356–362
Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Bookstein R, Bolen JB, Tavtigian SV, Steck PA . 1997 Cancer Res. 57: 5221–5225
Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J . 1998 Cancer Res. 58: 2720–2723
Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL . 1998 Proc. Natl. Acad. Sci. USA 95: 5246–5250
Wootton JC, Federhen S . 1996 Methods Enzymol. 266: 554–571
Yeh JJ, Marsh DJ, Zedenius J, Dwight T, Delbridge L, Robinson BG, Eng C . 1999 Genes Chrom. Cancer. 26: 322–328
Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI, Liu W . 1998 Int. J. Oncol. 13: 101–105
Acknowledgements
The GenBank accession number for the LAPSER1 cDNA is AY029201. This study was supported by NIH SPORE Grant P50-CA58204.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cabeza-Arvelaiz, Y., Thompson, T., Sepulveda, J. et al. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3. Oncogene 20, 6707–6717 (2001). https://doi.org/10.1038/sj.onc.1204866
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204866
Keywords
This article is cited by
-
Long non-coding RNA linc00921 suppresses tumorigenesis and epithelial-to-mesenchymal transition of triple-negative breast cancer via targeting miR-9-5p/LZTS2 axis
Human Cell (2022)
-
β-Trcp and CK1δ-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma
Oncogene (2021)
-
LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinoma
World Journal of Surgical Oncology (2018)
-
Physiological Role of β-Catenin/TCF Signaling in Neurons of the Adult Brain
Neurochemical Research (2013)
-
Fez1/Lzts1 a new mitotic regulator implicated in cancer development
Cell Division (2007)